Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
33.8M
-
Shares change
-
-6.12M
-
Total reported value, excl. options
-
$8.76M
-
Value change
-
-$4.44M
-
Put/Call ratio
-
0.06
-
Number of buys
-
32
-
Number of sells
-
-34
-
Price
-
$0.26
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q1 2025
86 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q1 2025.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.8M shares
of 62.3M outstanding shares and own 54.29% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (5.99M shares), BML Capital Management, LLC (5.89M shares), TANG CAPITAL MANAGEMENT LLC (4.76M shares), BlackRock, Inc. (3.18M shares), Aisling Capital Management LP (2.83M shares), VANGUARD GROUP INC (2.59M shares), GEODE CAPITAL MANAGEMENT, LLC (1.19M shares), STATE STREET CORP (1.06M shares), Ikarian Capital, LLC (690K shares), and RENAISSANCE TECHNOLOGIES LLC (647K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.